Transition from intravenous treprostinil to enteral selexipag in an infant with pulmonary arterial hypertension

被引：8
|
作者：
Koo, Rachel [1 ]
Lo, Jennifer [2 ]
Bock, Matthew J. [2 ]
机构：
[1] Loma Linda Univ Childrens Hlth, Dept Pediat, Loma Linda, CA USA
[2] Loma Linda Univ Childrens Hlth, Div Pediat Cardiol, Loma Linda, CA USA
来源：
CARDIOLOGY IN THE YOUNG | 2019年 / 29卷 / 06期
关键词：
Selexipag; infant; prostacyclin; pulmonary hypertension; paediatric;
D O I：
10.1017/S1047951119001082
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Selexipag is an enteral, selective prostacyclin IP receptor agonist approved for pulmonary hypertension in adults. There are few reports of its use in children and none in infants. We report the first transition of an infant (11.5 months, 8.6 kg) from intravenous treprostinil (40 ng/kg/minute) to enteral selexipag (400 mcg twice daily) with a good response and no adverse effects.
引用
收藏
页码：849 / 851
页数：3
相关论文
共 50 条
  • [21] Selexipag for the treatment of pulmonary arterial hypertension
    Richter, Manuel Jonas
    Gall, Henning
    Grimminger, Jan
    Grimminger, Friedrich
    Ghofrani, Hossein-Ardeschir
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (13) : 1825 - 1834
  • [22] Rapid Transition from Inhaled Iloprost to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension
    Bourge, Robert C.
    Tapson, Victor F.
    Safdar, Zeenat
    Benza, Raymond L.
    Channick, Richard N.
    Rosenzweig, Erika B.
    Shapiro, Shelley
    White, Richard James
    McSwain, Christopher Shane
    Gotzkowsky, Stephen Karl
    Nelsen, Andrew C.
    Rubin, Lewis J.
    CARDIOVASCULAR THERAPEUTICS, 2013, 31 (01) : 38 - 44
  • [23] Treprostinil in the treatment of pulmonary arterial hypertension
    Feldman, Jeremy
    Habib, Naomi
    Fann, Jade
    Radosevich, John J.
    FUTURE CARDIOLOGY, 2020, 16 (06) : 547 - 558
  • [24] Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension
    Raina, Amresh
    Coons, James C.
    Kanwar, Manreet
    Murali, Srinivas
    Sokos, George
    Benza, Raymond L.
    PULMONARY CIRCULATION, 2013, 3 (01) : 116 - 120
  • [25] Inhaled treprostinil and pulmonary arterial hypertension
    Nadler, Samuel T.
    Edelman, Jeffrey D.
    VASCULAR HEALTH AND RISK MANAGEMENT, 2010, 6 : 1115 - 1124
  • [26] Use of selexipag in a teenage patient with pulmonary arterial hypertension
    Bravo-Valenzuela, Nathalie Jeanne Magioli
    Navarro, Flavia
    Silva, Socrates Pereira
    ANNALS OF PEDIATRIC CARDIOLOGY, 2021, 14 (01) : 75 - 78
  • [27] Treprostinil for the treatment of pulmonary arterial hypertension
    Torres, Fernando
    Rubin, Lewis J.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2013, 11 (01) : 13 - 25
  • [28] Risk assessment and prognosis in patients with pulmonary arterial hypertension receiving intravenous treprostinil
    Olsson, Karen
    Richter, Manuel
    Kamp, Jan C.
    Gall, Henning
    Heine, Alexander
    Ghofrani, Hossein-Ardeshir
    Fuge, Jan
    Ewert, Ralf
    Hoeper, Marius M.
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [29] Intravenous treprostinil infusion via a fully implantable pump for pulmonary arterial hypertension
    Ewert, Ralf
    Richter, Manuel J.
    Steringer-Mascherbauer, Regina
    Gruenig, Ekkehard
    Lange, Tobias J.
    Opitz, Christian F.
    Warnke, Christian
    Ghofrani, Hossein-Ardeschir
    CLINICAL RESEARCH IN CARDIOLOGY, 2017, 106 (10) : 776 - 783
  • [30] Transition From Subcutaneous or Inhaled Treprostinil to Oral Treprostinil at Home in Patients With Pulmonary Arterial Hypertension: A Retrospective Case Series
    Ackerbauer, Kimberly A.
    Tandon, Rajive
    JOURNAL OF PHARMACY PRACTICE, 2018, 31 (02) : 163 - 166
12345